Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline

Connie B. Newman; Michael J. Blaha; Jeffrey B. Boord; Bertrand Cariou; Alan Chait; Henry G. Fein; Henry N. Ginsberg; Ira J. Goldberg; M. Hassan Murad; Savitha Subramanian; Lisa R. Tannock

doi:10.1210/clinem/dgaa674

Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline

Connie B. Newman, Michael J. Blaha, Jeffrey B. Boord, Bertrand Cariou, Alan Chait, Henry G. Fein, Henry N. Ginsberg, Ira J. Goldberg, M. Hassan Murad, Savitha Subramanian, Lisa R. Tannock

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.

Original language	English (US)
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	105
Issue number	12
DOIs	https://doi.org/10.1210/clinem/dgaa674
State	Published - Dec 1 2020

Keywords

Cardiovascular disease
Diabetes
Dyslipidemia
Endocrine diseases
Lipids
Triglycerides

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1210/clinem/dgaa674

Cite this

Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Hassan Murad, M., Subramanian, S., & Tannock, L. R. (2020). Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 105(12). https://doi.org/10.1210/clinem/dgaa674

@article{de7439afad4f4d71b73500b23706ff3a,

title = "Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline",

abstract = "Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.",

keywords = "Cardiovascular disease, Diabetes, Dyslipidemia, Endocrine diseases, Lipids, Triglycerides",

author = "Newman, {Connie B.} and Blaha, {Michael J.} and Boord, {Jeffrey B.} and Bertrand Cariou and Alan Chait and Fein, {Henry G.} and Ginsberg, {Henry N.} and Goldberg, {Ira J.} and {Hassan Murad}, M. and Savitha Subramanian and Tannock, {Lisa R.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

month = dec,

day = "1",

doi = "10.1210/clinem/dgaa674",

language = "English (US)",

volume = "105",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "12",

}

TY - JOUR

T1 - Lipid management in patients with endocrine disorders

T2 - An endocrine society clinical practice guideline

AU - Newman, Connie B.

AU - Blaha, Michael J.

AU - Boord, Jeffrey B.

AU - Cariou, Bertrand

AU - Chait, Alan

AU - Fein, Henry G.

AU - Ginsberg, Henry N.

AU - Goldberg, Ira J.

AU - Hassan Murad, M.

AU - Subramanian, Savitha

AU - Tannock, Lisa R.

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.

AB - Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.

KW - Cardiovascular disease

KW - Diabetes

KW - Dyslipidemia

KW - Endocrine diseases

KW - Lipids

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=85094933168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094933168&partnerID=8YFLogxK

U2 - 10.1210/clinem/dgaa674

DO - 10.1210/clinem/dgaa674

M3 - Review article

C2 - 32951056

AN - SCOPUS:85094933168

SN - 0021-972X

VL - 105

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 12

ER -

Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this